Ferring Pharmaceuticals SA, of Saint Prex, Switzerland, said its Cortiment (budesonide) treatment for the induction of remission in patients with active, mild to moderate ulcerative colitis has received marketing approval from 27 European Union member states following the EU Mutual Recognition Procedure.